Ellex Medical Lasers’ (ASX:ELX) proprietary Canaloplasty technology has been recognised as the new ‘gold standard’ in the surgical treatment of glaucoma by patient advocacy group The German Federate Eye Association.
This is a step towards the technology being recognised as the standard of care for glaucoma surgery worldwide.
The glaucoma surgical device market is valued at about A$275 million. This is expected to grow at an annual rate of 24% to reach $A$870 million by 2019.
Canaloplasty uses the company’s patented iTrack microcatheter to enlarge the eye’s natural drainage system.
Unlike traditional trabeculectomy surgery, which creates an artificial drainage channel, Canaloplasty restores the function of the eye’s natural outflow system in order to reduce the elevated intraocular pressure associated with glaucoma.
Being minimally invastive, Canaloplasty provides an improved safety profile and allows surgeons to reduce or eliminate many post-operative complications.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.